JP2019525897A5 - - Google Patents

Download PDF

Info

Publication number
JP2019525897A5
JP2019525897A5 JP2018563925A JP2018563925A JP2019525897A5 JP 2019525897 A5 JP2019525897 A5 JP 2019525897A5 JP 2018563925 A JP2018563925 A JP 2018563925A JP 2018563925 A JP2018563925 A JP 2018563925A JP 2019525897 A5 JP2019525897 A5 JP 2019525897A5
Authority
JP
Japan
Prior art keywords
immunoglobulin
residue
amino acid
item
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018563925A
Other languages
English (en)
Japanese (ja)
Other versions
JP7041077B2 (ja
JP2019525897A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2017/021672 external-priority patent/WO2017213267A1/en
Publication of JP2019525897A publication Critical patent/JP2019525897A/ja
Publication of JP2019525897A5 publication Critical patent/JP2019525897A5/ja
Application granted granted Critical
Publication of JP7041077B2 publication Critical patent/JP7041077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018563925A 2016-06-10 2017-06-12 リジン結合体化免疫グロブリン Active JP7041077B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348410P 2016-06-10 2016-06-10
US62/348,410 2016-06-10
PCT/JP2017/021672 WO2017213267A1 (en) 2016-06-10 2017-06-12 Lysine conjugated immunoglobulins

Publications (3)

Publication Number Publication Date
JP2019525897A JP2019525897A (ja) 2019-09-12
JP2019525897A5 true JP2019525897A5 (OSRAM) 2020-07-16
JP7041077B2 JP7041077B2 (ja) 2022-03-23

Family

ID=59315675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563925A Active JP7041077B2 (ja) 2016-06-10 2017-06-12 リジン結合体化免疫グロブリン

Country Status (21)

Country Link
US (2) US10941431B2 (OSRAM)
EP (1) EP3468614A1 (OSRAM)
JP (1) JP7041077B2 (OSRAM)
KR (1) KR102538866B1 (OSRAM)
CN (1) CN109475642B (OSRAM)
AU (1) AU2017279352B2 (OSRAM)
BR (1) BR112018075253A2 (OSRAM)
CA (1) CA3026991A1 (OSRAM)
CL (1) CL2021003383A1 (OSRAM)
CO (1) CO2018013314A2 (OSRAM)
IL (1) IL263329B (OSRAM)
JO (1) JOP20180118A1 (OSRAM)
MX (1) MX419566B (OSRAM)
MY (1) MY202858A (OSRAM)
NZ (1) NZ748605A (OSRAM)
PE (1) PE20190340A1 (OSRAM)
PH (1) PH12018502594A1 (OSRAM)
RU (2) RU2021136863A (OSRAM)
SG (1) SG11201810470XA (OSRAM)
UA (1) UA126799C2 (OSRAM)
WO (1) WO2017213267A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018007451A (es) 2015-12-18 2018-11-09 Eisai R&D Man Co Ltd Inmunoglobulinas conjugadas con lisina c-terminal.
CA3026991A1 (en) 2016-06-10 2017-12-14 Eisai R&D Management Co., Ltd. Lysine conjugated immunoglobulins
MA55884A (fr) * 2019-05-09 2022-03-16 Merus Nv Domaines variants pour la multimérisation de protéines et leur séparation
GB201907093D0 (en) * 2019-05-20 2019-07-03 Ucl Business Plc Antibody functionalisation
CN115335406B (zh) * 2020-02-12 2026-01-30 伊莱利利公司 抗体或抗原-结合片段的结晶
US20230242671A1 (en) * 2020-03-25 2023-08-03 Eli Lilly And Company Multispecific binding proteins and methods of developing the same
JP7787101B2 (ja) * 2020-05-20 2025-12-16 ヤンセン バイオテツク,インコーポレーテツド グリコシル化Fcドメインを含むタンパク質の部位特異的コンジュゲーションのための方法
CA3193819A1 (en) * 2020-09-25 2022-03-31 Anne De Groot Retro-inverso regulatory t cell epitopes
KR20240049342A (ko) * 2021-08-27 2024-04-16 얀센 바이오테크 인코포레이티드 항-psma 항체 및 이의 용도
CN115947830B (zh) * 2022-12-27 2023-09-12 优洛生物(上海)有限公司 一种经改造的抗体、其制备方法及其用途
WO2024182569A2 (en) 2023-02-28 2024-09-06 Eisai R&D Management Co., Ltd. Anti-psma antibodies, conjugates, and methods of use
WO2024211135A2 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Characterization of crosslinking sites in antibody-drug conjugates
CN119375471A (zh) * 2023-07-26 2025-01-28 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途
WO2025199464A1 (en) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途
WO2026044149A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Synthesis of drug-linker combinations for antibody-drug conjugates
WO2026044039A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Anti-cd73 antibodies, conjugates, and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
ES2642214T3 (es) * 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
CA2930801C (en) * 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013176516A1 (ko) 2012-05-24 2013-11-28 한화케미칼 주식회사 트랜스글루타미나아제를 이용하여 제조한 항체-약물 결합체 및 이의 용도
EP2916872B1 (en) * 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
JP6744212B2 (ja) * 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. ポリペプチドの酵素的結合
BR112016000585A2 (pt) * 2013-07-11 2018-03-20 Novartis Ag modificações quimioenzimáticas sítio-específicas de proteína
EP3027224B1 (en) * 2013-07-31 2020-06-03 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
CN106456798B (zh) 2014-04-25 2021-02-12 瑞纳神经科学公司 具有高药物负载的抗体-药物缀合物
MX2018007451A (es) * 2015-12-18 2018-11-09 Eisai R&D Man Co Ltd Inmunoglobulinas conjugadas con lisina c-terminal.
CA3026991A1 (en) 2016-06-10 2017-12-14 Eisai R&D Management Co., Ltd. Lysine conjugated immunoglobulins

Similar Documents

Publication Publication Date Title
JP2019502684A5 (OSRAM)
JP7133611B2 (ja) 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体
ES2277344T3 (es) Purificacion de anticuerpos mediante cromatografia de interaccion hidrofobica a ph bajo.
ES2549077T3 (es) Espectrometría de masas de conjugados de anticuerpos
CN109475642B (zh) 赖氨酸缀合的免疫球蛋白
JP6585600B2 (ja) C末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法
BR112015023589B1 (pt) Método para a produção de um conjugado de imunoligante/carga útil
JP7514836B2 (ja) トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途
RU2018126304A (ru) Конъюгированные иммуноглобулины с c-концевым лизином
CN111712520A (zh) 磷脂酰肌醇聚糖3抗体及其偶联物
JP2018520092A5 (OSRAM)
WO2012059882A2 (en) Engineered polypeptide conjugates and methods for making thereof using transglutaminase
JP7339291B2 (ja) シクロホスファミド及びイホスファミドのイムノアッセイ用の免疫原及びアッセイ接合体として用いるシクロホスファミド類似体
US20220267467A1 (en) Polypeptide complex for conjugation and use thereof
CN107029242A (zh) 抗体药物复合物及其制造方法
CN110799537A (zh) 抗pd-1抗体及其制备和使用方法
JP2024545170A5 (OSRAM)
CN108601848A (zh) 用于制备细胞结合剂-细胞毒性剂缀合物的有效方法
AU2019386945B2 (en) Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses
TWI591176B (zh) 抗liv-1之人化抗體類及彼等於治療癌症上之用途
CA3008645C (en) C-terminal lysine conjugated immunoglobulins
KR20250045545A (ko) 항체-킬레이터 콘쥬게이트
JP2024500921A (ja) 開環チオスクシンイミド基、オリゴペプチドフラグメント及びキラル部分を含む新規異性化合物
NZ751907B2 (en) Anti-muc16 (mucin 16) antibodies
BR112016018005B1 (pt) Conjugados anticorpo-droga e imunotoxinas